← Leaderboards
Rachita Sumbria
Keck Graduate Inst Of Applied Life Scis
$4,336,947
Attributed
$5,683,847
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,683,847 · 5
By mechanism
R01$4,895,715 · 3
R21$788,132 · 2
Top collaborators
- Derick S Han11 shared
Most similar at Keck Graduate Inst Of Applied Life Scis
Same institution · by research overlap
- Yao Liang Tang$6,672,201
- Jeniffer Bertha Hernandez$767,893
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposAmyloid Beta-ProteinChronicPeripheralBrainS DiseaseBlood - Brain Barrier AnatomyMediatingTau ProteinsChimeric ProteinsReceptorInflammationTnf GeneS Disease PathologyEtanerceptBiological ProductsPathologyHomeostasisNeuroinflammationInsightFc ReceptorEndotheliumOverexpressionLipoprotein Receptor
Grant awards (21)
Efficacy, safety, and mechanisms of brain penetrable erythropoietin in Alzheimerâs disease mouse models$335,160
R01 · FY2025 · AG · contact PI
The impact of obesity-induced hepatic amyloid beta dysregulation on Alzheimerâs disease pathology$405,849
R21 · FY2024 · AG
Modulation of the liver-brain axis by alcohol and its impact on Alzheimers disease pathology$375,519
R01 · FY2024 · AG
Efficacy, safety, and mechanisms of brain penetrable erythropoietin in Alzheimerâs disease mouse models$342,000
R01 · FY2024 · AG · contact PI
A Brain Penetrating Bi-functional Transferrin Receptor Antibody-TNF-alpha Decoy Receptor Fusion Protein for Alzheimer's Disease$245,000
R01 · FY2024 · AG · contact PI
Modulation of the liver-brain axis by alcohol and its impact on Alzheimers disease pathology$83,347
R01 · FY2024 · AG
Modulation of the liver-brain axis by alcohol and its impact on Alzheimers disease pathology$55,565
R01 · FY2024 · AG
Modulation of the liver-brain axis by alcohol and its impact on Alzheimers disease pathology$427,374
R01 · FY2023 · AG
A Brain Penetrating Bi-functional Transferrin Receptor Antibody-TNF-alpha Decoy Receptor Fusion Protein for Alzheimer's Disease$377,708
R01 · FY2023 · AG · contact PI
Modulation of the liver-brain axis by alcohol and its impact on Alzheimers disease pathology$378,443
R01 · FY2022 · AG
A Brain Penetrating Bi-functional Transferrin Receptor Antibody-TNF-alpha Decoy Receptor Fusion Protein for Alzheimer's Disease$377,708
R01 · FY2022 · AG · contact PI
Modulation of the liver-brain axis by alcohol and its impact on Alzheimers disease pathology$77,782
R01 · FY2022 · AG
Modulation of the liver-brain axis by alcohol and its impact on Alzheimers disease pathology$25,927
R01 · FY2022 · AG
Modulation of the liver-brain axis by alcohol and its impact on Alzheimers disease pathology$390,918
R01 · FY2021 · AG
A Brain Penetrating Bi-functional Transferrin Receptor Antibody-TNF-alpha Decoy Receptor Fusion Protein for Alzheimer's Disease$377,708
R01 · FY2021 · AG · contact PI
Modulation of the liver-brain axis by alcohol and its impact on Alzheimers disease pathology$85,083
R01 · FY2021 · AG
Modulation of the liver-brain axis by alcohol and its impact on Alzheimers disease pathology$387,994
R01 · FY2020 · AG
A Brain Penetrating Bi-functional Transferrin Receptor Antibody-TNF-alpha Decoy Receptor Fusion Protein for Alzheimer's Disease$162,296
R01 · FY2020 · AG · contact PI
A Brain Penetrating Bi-functional Transferrin Receptor Antibody-TNF-alpha Decoy Receptor Fusion Protein for Alzheimer's Disease$390,183
R01 · FY2019 · AG · contact PI
Re-engineering Erythropoietin for Alzheimer's Disease$186,852
R21 · FY2018 · AG · contact PI
Re-engineering Erythropoietin for Alzheimer's Disease$195,431
R21 · FY2017 · AG · contact PI